Drug recall · February 24, 2021
Cephalexin for Oral Suspension recall
Why: CGMP Deviations: Individual Unidentified impurities results of the product was found at higher side of the specification limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cephalexin for Oral Suspension, USP 250 mg per 5 mL 200 ml (when mixed) Rx Only, Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-545-68
- Lots / codes
Lot #: 19141869, 19141870, EXP 3/2021; 19142762, EXP 5/2021; 19143826, 19143923,19143941, 19143954 EXP 7/2021
- Quantity
- 23,436 200 mL bottles
- Company
- Ascend Laboratories LLC, Parsippany, NJ
- Distribution
- Nationwide in the USA
- Initiated
- January 22, 2021 · Voluntary: Firm initiated
- Classified
- February 18, 2021
- Reported
- February 24, 2021
- Ended
- December 2, 2022
- How notified
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cephalexin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.